
rastuzumab, a monoclonal anti-body targeting the extracellular domain ofthe HER2 protein, was approved in 1998
as a first-line treatment in combination with pacli-taxel for HER2-positive metastatic breast cancer.1The benefit of this approach in patients with meta-static disease and the poor prognosis of HER2-pos-itive breast cancer2,3 motivated the National Can-cer Institute (NCI) to sponsor two trials of adjuvanttreatment with trastuzumab, led by the NationalSurgical Adjuvant Breast and Bowel Project (NSABP)and the North Central Cancer Treatment Group(NCCTG).
NSABP trial B-31, which began accrual in Febru-ary 2000, compares four cycles of doxorubicin andcyclophosphamide followed by paclitaxel (group 1)with the same chemotherapy plus 52 weeks of tras-tuzumab beginning on day 1 of paclitaxel therapy(group 2). NCCTG trial N9831 began enrollmentin May 2000 and compares three regimens: fourcycles of doxorubicin and cyclophosphamide fol-lowed by weekly paclitaxel for 12 weeks (group A),four cycles of doxorubicin and cyclophosphamidefollowed by 52 weeks of trastuzumab after the com-pletion of paclitaxel therapy (group B), and fourcycles of doxorubicin and cyclophosphamide fol-lowed by 52 weeks of trastuzumab beginning onday 1 of paclitaxel therapy (group C).
The control groups of the trials, as well as group2 in trial B-31 and group C in trial N9831, differedin terms of the scheduling of paclitaxel treatmentand some aspects of hormonal therapy and radio-therapy but were otherwise identical. For this rea-son, the NCI and the Food and Drug Administra-tion approved a joint-analysis plan developed by theNSABP and NCCTG to combine data from group 1and group A (referred to as the control group) forcomparison with group 2 and group C (referred toas the trastuzumab group). Group B of trial N9831was excluded because the protocol required tras-tuzumab to be administered after the completionof chemotherapy.
The plan required a first interim analysis afterthe occurrence of 355 events. Before the data werelocked, 2043 patients (of a planned total of 2700)were enrolled in trial B-31 and 1633 patients (of atotal of 2000 for the comparison of group A withgroup C) were enrolled in trial N9831. In April 2005,the independent data-monitoring committees ofeach trial recommended closing enrollment andreleasing the results.
t
The new england journal of medicine
Enrollment required a pathological diagnosis ofadenocarcinoma of the breast with immunohisto-chemical staining for HER2 protein of 3+ intensityor amplification of the HER2 gene on fluorescencein situ hybridization. Initially, both trials requiredpatients to have histologically proven, node-posi-tive disease; as of May 2, 2003, patients with high-risk node-negative disease (defined as a tumor thatwas more than 2 cm in diameter and positive forestrogen receptors or progesterone receptors oras a tumor that was more than 1 cm in diameterand negative for both estrogen receptors and pro-gesterone receptors) were eligible for trial N9831.Other requirements were adequate hematopoiet-ic, hepatic, and renal function and a left ventricu-lar ejection fraction (LVEF) that met or exceededthe lower limit of normal. Patients with clinical orradiologic evidence of metastatic disease were ex-cluded. Findings suggestive of metastasis were con-firmed or refuted by additional radiologic evalua-tion or biopsy. Complete resection of the primarytumor and axillary-node dissection were required(negative sentinel-node biopsy was allowed in trialN9831). Patients were ineligible if they had anginapectoris requiring antianginal medication, arrhyth-mia requiring medication, a severe conduction ab-normality, clinically significant valvular disease,cardiomegaly on chest radiography, left ventricularhypertrophy on echocardiography (trial B-31 only),poorly controlled hypertension, clinically signifi-cant pericardial effusion (trial N9831 only), or ahistory of myocardial infarction, congestive heartfailure, or cardiomyopathy.
Participating institutions obtained the approvalof their human investigations committee or insti-tutional review board and filed assurances with theDepartment of Health and Human Services. Writ-ten informed consent was required for enrollment.In trial B-31, treatment assignments were bal-anced according to nodal status, the planned hor-monal therapy, the type of surgery (lumpectomy vs.mastectomy), the intended radiotherapy, and insti-tution with the use of a biased-coin minimizationalgorithm.4 Trial N9831 used a dynamic allocationprocedure that balanced the marginal distributionsof nodal status and hormone-receptor status be-tween groups.5 The procedures used for HER2 test-ing in the two trials are provided in the Supple-
1674n engl j med 353;16
doc.guandang.net
october 20, 2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer 〔J〕 Engl J Med,2005, .N 353(16):1673-1684. [2] Piccart-Gebhart MJ,...
曲妥珠单抗联合辅助化疗用于HER2阳性可手术乳腺癌的评价_专业资料。1文献来源 ...al.Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast ...
Molecular portraits of human breast Tumors [J]. Nature ,2000 ,406 (6797 ...Trastuzumab plus adjuvant chemotherapy for operable HER2 -positive beast carcer...
Trastuzumab plus adjuvant chemotherapy can improve disease-free survivalrate, ...Trastuzumab plusa djuvant chemotherapy for operable HER2-positive breast cancer...
TAXOL? (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer ...? ? ? Paclitaxel Docetaxel Capecitabine Trastuzumab Adjuvant Chemotherapy of ...
in stage II or III HER2-positive breast cancer...Cancer. 2007 Trastuzumab plus vinorelbine or taxane...Dose-dense adjuvant chemotherapy in node-positive ...
adjuvant or metastatic HER2-positive invasive breast cancer.6-8 In the ...trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor...
Operable HER2-Positive Breast Cancer Comparing the... to Chemotherapy Plus Trastuzumab in Women with ...Adjuvant Chemotherapy for Radically Resected Loco-...
chemotherapy. words:trastuzumab;humanepidermalgrow...adjuvantvfft-51腮adJuvantsystemictreatmentinbreastcan...(P)plus uusmzumab∞in Her2positiveprimarybreast ...
2-year follow-up of et trastuzumab after adjuvant chemotherapy in HER2 positive breast ...Neoadjuvant paclitaxel et for operable breast cancer...
热门文档